Vanda Pharmaceuticals Financial Statements (VNDA)
|
|
|
|
Report date
|
|
|
26.02.2020 |
11.02.2021 |
24.02.2022 |
09.02.2023 |
08.02.2024 |
|
07.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
227.2 |
248.2 |
268.7 |
254.4 |
192.6 |
|
190.9 |
|
Operating Income, bln rub |
|
|
22.8 |
27.2 |
42.2 |
6.33 |
-14.0 |
|
-37.5 |
|
EBITDA, bln rub |
? |
|
25.7 |
30.1 |
45.0 |
9.06 |
-10.9 |
|
-32.1 |
|
Net profit, bln rub |
? |
|
115.6 |
23.3 |
33.2 |
6.28 |
2.51 |
|
-16.4 |
|
|
OCF, bln rub |
? |
|
45.9 |
51.8 |
64.2 |
32.0 |
12.8 |
|
-17.7 |
|
CAPEX, bln rub |
? |
|
1.02 |
1.80 |
0.552 |
0.679 |
0.383 |
|
0.529 |
|
FCF, bln rub |
? |
|
44.9 |
50.0 |
63.7 |
31.3 |
12.4 |
|
-18.2 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
179.9 |
197.6 |
200.9 |
223.8 |
191.8 |
|
214.9 |
|
Cost of production, bln rub |
|
|
24.5 |
23.4 |
25.6 |
24.3 |
14.8 |
|
16.0 |
|
R&D, bln rub |
|
|
48.6 |
55.6 |
75.4 |
85.8 |
76.8 |
|
78.9 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Assets, bln rub |
|
|
483.7 |
533.5 |
593.8 |
634.2 |
648.4 |
|
645.1 |
|
Net Assets, bln rub |
? |
|
410.9 |
453.3 |
504.9 |
527.2 |
544.9 |
|
541.2 |
|
Debt, bln rub |
|
|
12.5 |
13.6 |
10.1 |
11.1 |
9.40 |
|
5.49 |
|
Cash, bln rub |
|
|
312.1 |
367.7 |
432.8 |
466.9 |
388.3 |
|
376.3 |
|
Net debt, bln rub |
|
|
-299.7 |
-354.1 |
-422.8 |
-455.7 |
-378.9 |
|
-370.8 |
|
|
Ordinary share price, rub |
|
|
16.4 |
13.1 |
15.7 |
7.39 |
4.22 |
|
4.47 |
|
Number of ordinary shares, mln |
|
|
53.1 |
54.4 |
55.5 |
56.5 |
57.4 |
|
58.3 |
|
|
Market cap, bln rub |
|
|
872 |
715 |
872 |
417 |
242 |
|
260 |
|
EV, bln rub |
? |
|
572 |
361 |
449 |
-38 |
-137 |
|
-110 |
|
Book value, bln rub |
|
|
388 |
432 |
485 |
509 |
424 |
|
425 |
|
|
EPS, rub |
? |
|
2.17 |
0.43 |
0.60 |
0.11 |
0.04 |
|
-0.28 |
|
FCF/share, rub |
|
|
0.85 |
0.92 |
1.15 |
0.55 |
0.22 |
|
-0.31 |
|
BV/share, rub |
|
|
7.30 |
7.93 |
8.73 |
9.01 |
7.38 |
|
7.30 |
|
|
EBITDA margin, % |
? |
|
11.3% |
12.1% |
16.8% |
3.56% |
-5.68% |
|
-16.8% |
|
Net margin, % |
? |
|
50.9% |
9.40% |
12.3% |
2.47% |
1.30% |
|
-8.59% |
|
FCF yield, % |
? |
|
5.15% |
6.99% |
7.30% |
7.50% |
5.13% |
|
-6.99% |
|
ROE, % |
? |
|
28.1% |
5.15% |
6.57% |
1.19% |
0.46% |
|
-3.03% |
|
ROA, % |
? |
|
23.9% |
4.37% |
5.58% |
0.99% |
0.39% |
|
-2.54% |
|
|
P/E |
? |
|
7.55 |
30.6 |
26.3 |
66.5 |
96.5 |
|
-15.9 |
|
P/FCF |
|
|
19.4 |
14.3 |
13.7 |
13.3 |
19.5 |
|
-14.3 |
|
P/S |
? |
|
3.84 |
2.88 |
3.24 |
1.64 |
1.26 |
|
1.36 |
|
P/BV |
? |
|
2.25 |
1.66 |
1.80 |
0.82 |
0.57 |
|
0.61 |
|
EV/EBITDA |
? |
|
22.3 |
12.0 |
9.97 |
-4.24 |
12.5 |
|
3.43 |
|
Debt/EBITDA |
|
|
-11.7 |
-11.8 |
-9.39 |
-50.3 |
34.6 |
|
11.5 |
|
|
R&D/CAPEX, % |
|
|
4 774% |
3 096% |
13 653% |
12 632% |
20 058% |
|
14 921% |
|
|
CAPEX/Revenue, % |
|
|
0.45% |
0.72% |
0.21% |
0.27% |
0.20% |
|
0.28% |
|
| Vanda Pharmaceuticals shareholders |
